Roxadustat shows the latest regulatory fault line split
Fibrogen’s controversial anaemia pill becomes the latest example of markedly different regulatory stances taken in Europe and the US.
No hiding the Toledo disappointment for Galapagos
GLPG3970 is biologically inert in ulcerative colitis and rheumatoid arthritis, so Galapagos’s search for something better goes on.
Go or no go? Ardelyx and Chemocentryx among those waiting FDA decisions
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
Esker joins the Tyk2 race
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
Bristol’s Tyk2 ticks the boxes
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
Biotech’s important clinical data readouts
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Gilead’s Galapagos hopes now rest on Toledo
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
